Literature DB >> 8900424

Renal-cell carcinoma-specific lysis by cytotoxic T-lymphocyte clones isolated from peripheral blood lymphocytes and tumor-infiltrating lymphocytes.

N Brouwenstijn1, B Gaugler, K M Krüse, C W van der Spek, A Mulder, S Osanto, B J van den Eynde, P I Schrier.   

Abstract

Melanoma and renal-cell carcinoma (RCC) are generally considered to be relatively immunogenic tumor types in humans. In the case of melanoma, many major histocompatibility complex (MHC) class I-restricted tumor-specific cytotoxic T lymphocytes (CTL) have been isolated from either tumor-infiltrating lymphocytes (TIL) or autologous peripheral blood lymphocytes (PBL). In contrast, such CTL have only incidentally been described in the case of RCC. It has often been reported that TIL lines isolated from RCC display non-MHC-restricted and non-specific activity. Here, we report the isolation and characterization of tumor-specific CTL from PBL of one RCC patient and from TIL of another RCC patient. CTL clones 263/17 and 263/45, isolated from the PBL of patient LE-9211, were restricted by HLA-B7. CTL clone 5E, isolated from the TIL of patient LE-8915, was restricted by HLA-B37. The autologous RCC cell lines were efficiently lysed by the CTL clones, whereas normal epithelial cells of the proximal tubuli matched for the restriction element and K562 were not. From a panel of allogeneic RCC cell lines, CTL 5E recognized MZ-1940-RCC. Reactivity to allogeneic RCC sharing HLA-B7 was also observed with CTL 263/17 and 263/45, both of which could lyse the HLA-B7-positive cell line MZ-1851-RCC. Our data provide evidence that common tumor antigens are recognized by CTL on RCC.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8900424     DOI: 10.1002/(SICI)1097-0215(19961009)68:2<177::AID-IJC6>3.0.CO;2-V

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  11 in total

Review 1.  Allogeneic hematopoietic cell transplantation for renal cell carcinoma: ten years after.

Authors:  Scott S Tykodi; Brenda M Sandmaier; Edus H Warren; John A Thompson
Journal:  Expert Opin Biol Ther       Date:  2011-03-21       Impact factor: 4.388

Review 2.  Lymphocyte subpopulation and dendritic cell phenotyping during antineoplastic therapy in human solid tumors.

Authors:  Sara Mariucci; Bianca Rovati; Mariangela Manzoni; Matteo Giovanni Della Porta; Giuditta Comolli; Sara Delfanti; Marco Danova
Journal:  Clin Exp Med       Date:  2010-12-16       Impact factor: 3.984

3.  Prognostic histological and immune markers of renal cell carcinoma.

Authors:  T Magyarlaki; I Buzogány; L Kaiser; F Sükösd; R Döbrönte; B Simon; A Fazekas; J Nagy
Journal:  Pathol Oncol Res       Date:  2001       Impact factor: 3.201

Review 4.  Allogeneic stem-cell transplantation in renal-cell carcinoma.

Authors:  B M Hayes-Lattin; R T Maziarz; T M Beer
Journal:  Curr Oncol Rep       Date:  2001-09       Impact factor: 5.075

5.  A new gene coding for an antigen recognized by autologous cytolytic T lymphocytes on a human renal carcinoma.

Authors:  B Gaugler; N Brouwenstijn; V Vantomme; J P Szikora; C W Van der Spek; J J Patard; T Boon; P Schrier; B J Van den Eynde
Journal:  Immunogenetics       Date:  1996       Impact factor: 2.846

6.  Immunotherapy for renal cell carcinoma.

Authors:  Momoe Itsumi; Katsunori Tatsugami
Journal:  Clin Dev Immunol       Date:  2011-01-03

7.  A new antigen recognized by cytolytic T lymphocytes on a human kidney tumor results from reverse strand transcription.

Authors:  B J Van Den Eynde; B Gaugler; M Probst-Kepper; L Michaux; O Devuyst; F Lorge; P Weynants; T Boon
Journal:  J Exp Med       Date:  1999-12-20       Impact factor: 14.307

8.  Enhanced expression of IFN-gamma mRNA in CD4(+)or CD8(+)tumour-infiltrating lymphocytes compared to peripheral lymphocytes in patients with renal cell cancer.

Authors:  U Elsässer-Beile; M Rindsfüser; T Grussenmeyer; W Schultze-Seemann; U Wetterauer
Journal:  Br J Cancer       Date:  2000-09       Impact factor: 7.640

9.  Full response of a localized renal tumour after reduced-intensity conditioned hematopoietic stem cell transplantation.

Authors:  Anne-Claire Gac; Sylvain Chantepie; Michel Leporrier; Oumedaly Reman
Journal:  Case Rep Med       Date:  2009-11-12

10.  A pilot clinical trial testing mutant von Hippel-Lindau peptide as a novel immune therapy in metastatic renal cell carcinoma.

Authors:  Osama E Rahma; Ed Ashtar; Ramy Ibrahim; Antoun Toubaji; Barry Gause; Vincent E Herrin; W Marston Linehan; Seth M Steinberg; Frank Grollman; George Grimes; Sarah A Bernstein; Jay A Berzofsky; Samir N Khleif
Journal:  J Transl Med       Date:  2010-01-28       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.